Serum levels of selenium in patients with brain metastases from non-small cell lung cancer before and after radiotherapy

Zeng, Yaqi; Xue, Menghua; Chi, Feng; Xu, Zhihao; Fan, Guoguang; Fan, Yaqin; Zheng, Min; Zhong, W.; Wang, S.L.; Zhang, Z.Y.; Chen, X.D.; Wu, Lei; Jin, Xu Yu; Chen, W.; Li, Q.; Zhang, X.Y.; Xiao, Yu; Wu, Runmiao; Guo, Qiujun

doi:10.1016/j.canrad.2011.11.003

Cited by 15 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, It was noted in patients treated by radiotherapy for breast cancer that the mean serum Se level dropped from 86.4 μg/l before radiotherapy to 47.8 μg/l after it (15). In another study of 95 patients with brain metastases from non-small cell lung cancer, the mean plasma Se level decreased from 90.4 μg/l before radiotherapy to 56.3 μg/l after radiotherapy of the brain metastases (16) and this difference was statistically significant in a multivariate analysis independently of age, body mass index, smoking, alcoholism, prior chemotherapy and pathological types. This is why Se treatments have been discussed for reducing radiation-associated side-effects (17,18), but without definitive conclusions.…”

Section: Discussionmentioning

confidence: 99%

Negative Impact of Total Body Irradiation on the Antitumor Activity of Rhenium-(I)-diselenoether

Collery¹,

Santoni

Mohsen

et al. 2016

View full text Add to dashboard Cite

Abstract. It has been shown that a rhenium-(I)-It has been shown that a prolonged oral administration of amphiphilic rhenium-(I)-diselenoether complex allowed a dose-dependent uptake of the two major components of this drug, rhenium (Re) and selenium (Se) in healthy tissues, with highest uptake by the liver (1). Assays of these two elements have not yet been performed in tumorsThe combination of Se with a metal has already been described, with nickel as the metal (2). In that case, the presence of Se in the active site of hydrogenase enhanced its enzymatic property. Selective incorporation of Se into the active site of the molybdenum-iron (Mo-Fe) protein is essential for the catalytical effect of nitrogenase (3). Ironselenium ferredoxin with two clusters [4Fe-4Se] is present in the active site of a hydrogenase (4), with the same role as the iron-sulfur ferredoxin as a two-electron carrier.It is known that Re is able to bind DNA reversibly and that Re is found in the nucleus of malignant cells after the administration of Re-diselenoether (1, 5). It was also shown that the Re-diselenoether formed mono-adducts and bisadducts with a methyl-guanine, but also liberated the weakly chelating diselenoether ligand [supplementary material in (5)].Therefore we can hypothesize that while the Re core will have a role by interacting with DNA guanine bases, the diselenoether ligand will take Se to other targets.The anticancer activity of Re-diselenother has been demonstrated in experimental models of resistant triplenegative breast tumors (MDA-MB231), in malignant cells in culture, as well as after oral (5) or intraperitoneal administration (6) to tumor-bearing mice, at a daily dose of 10 mg/kg/day for 4 weeks, which was safe for the animals. The Re-diseleno ether compound we used, constituted an original chemical combination, and we aimed to complete the investigation of its biological role in an experimental model of cancer.The aim of this experiment was to test a lower dose of 5 mg/kg and to compare it with a 10-mg/kg dose. We evaluated the Re-complex as a single agent and in combination with paclitaxel, considered as a standard 5813

show abstract

Section: Discussionmentioning

confidence: 99%

Negative Impact of Total Body Irradiation on the Antitumor Activity of Rhenium-(I)-diselenoether

Collery¹,

Santoni

Mohsen

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some evidence have shown that cancer patients may have lower levels of selenium compared with healthy individuals . Some clinical investigations have also shown that radiotherapy may reduce the level of selenium in cancer patients . Furthermore, it has been revealed that reduction of selenium is associated with increased levels of oxidative stress markers and reduction of antioxidant defense in patients who had undergone radiotherapy, leading to higher toxicities in normal tissues such as mucositis …”

Section: Clinical Evidence For Selenium In Radiotherapymentioning

confidence: 99%

“…94 Some clinical investigations have also shown that radiotherapy may reduce the level of selenium in cancer patients. 95,96 Furthermore, it has been revealed that reduction of selenium is associated with increased levels of oxidative stress markers and reduction of antioxidant defense in patients who had undergone radiotherapy, leading to higher toxicities in normal tissues such as mucositis. 97,98 Selenium supplement has shown the ability to alleviate toxicities to normal tissues for patients who had undergone cancer treatment.…”

Section: Selenium In Radiotherapymentioning

confidence: 99%

Selenium as an adjuvant for modification of radiation response

Farhood

Mortezaee

Motevaseli

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Ionizing radiation plays a central role in several medical and industrial purposes. In spite of the beneficial effects of ionizing radiation, there are some concerns related to accidental exposure that could pose a threat to the lives of exposed people. This issue is also very critical for triage of injured people in a possible terror event or nuclear disaster. The most common side effects of ionizing radiation are experienced in cancer patients who had undergone radiotherapy. For complete eradication of tumors, there is a need for high doses of ionizing radiation. However, these high doses lead to severe toxicities in adjacent organs. Management of normal tissue toxicity may be achieved via modulation of radiation responses in both normal and malignant cells. It has been suggested that treatment of patients with some adjuvant agents may be useful for amelioration of radiation toxicity or sensitization of tumor cells. However, there are always some concerns for possible severe toxicities and protection of tumor cells, which in turn affect radiotherapy outcomes. Selenium is a trace element in the body that has shown potent antioxidant and radioprotective effects for many years. Selenium can potently stimulate antioxidant defense of cells, especially via upregulation of glutathione (GSH) level and glutathione peroxidase activity. Some studies in recent years have shown that selenium is able to mitigate radiation toxicity when administered after exposure. These studies suggest that selenium may be a useful radiomitigator for an accidental radiation event. Molecular and cellular studies have revealed that selenium protects different normal cells against radiation, while it may sensitize tumor cells. These differential effects of selenium have also been revealed in some clinical studies. In the present study, we aimed to review the radiomitigative and radioprotective effects of selenium on normal cells/tissues, as well as its radiosensitive effect on cancer cells.

show abstract

“…Selenium levels had a tendency to decrease after radiotherapy and to increase with selenium supplementation. The mechanism of this decrease is still unclear [24,25]. Pothier et al suggested that poor dietary intake due to anorexia, nausea, and obstruction, compounded by selenium loss from vomiting, diarrhea, and malabsorption, probably played a role in the decrease [17].…”

Section: Methodsmentioning

confidence: 99%

Updates on clinical studies of selenium supplementation in radiotherapy

et al. 2014

View full text Add to dashboard Cite

To establish guidelines for the selenium supplementation in radiotherapy we assessed the benefits and risks of selenium supplementation in radiotherapy. Clinical studies on the use of selenium in radiotherapy were searched in the PubMed electronic database in January 2013. Sixteen clinical studies were identified among the 167 articles selected in the initial search. Ten articles were observational studies, and the other 6 articles reported studies on the effects of selenium supplementation in patients with cancer who underwent radiotherapy. The studies were conducted worldwide including European, American and Asian countries between 1987 and 2012. Plasma, serum or whole blood selenium levels were common parameters used to assess the effects of radiotherapy and the selenium supplementation status. Selenium supplementation improved the general conditions of the patients, improved their quality of life and reduced the side effects of radiotherapy. At the dose of selenium used in these studies (200–500 μg/day), selenium supplementation did not reduce the effectiveness of radiotherapy, and no toxicities were reported. Selenium supplementation may offer specific benefits for several types of cancer patients who undergo radiotherapy. Because high-dose selenium and long-term supplementation may be unsafe due to selenium toxicity, more evidence-based information and additional research are needed to ensure the therapeutic benefits of selenium supplementation.

show abstract

Serum levels of selenium in patients with brain metastases from non-small cell lung cancer before and after radiotherapy

Cited by 15 publications

References 22 publications

Negative Impact of Total Body Irradiation on the Antitumor Activity of Rhenium-(I)-diselenoether

Negative Impact of Total Body Irradiation on the Antitumor Activity of Rhenium-(I)-diselenoether

Selenium as an adjuvant for modification of radiation response

Updates on clinical studies of selenium supplementation in radiotherapy

Contact Info

Product

Resources

About